<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900558</url>
  </required_header>
  <id_info>
    <org_study_id>19303_oss</org_study_id>
    <nct_id>NCT04900558</nct_id>
  </id_info>
  <brief_title>Robotic Radical Cystectomy Outcomes</brief_title>
  <official_title>Impact of Robotic Surgery on Post-operative Outcomes of Patients Who Underwent Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, in the treatment of bladder cancer the use of robotics has entered in clinical&#xD;
      practice, therefor robotic radical cystectomy with or without reconstruction is offered to&#xD;
      patients during counseling procedures, if deemed appropriate and possible. The aim of the&#xD;
      study is therefore the long-term evaluation of the peri-post-operative, oncological and&#xD;
      functional results of patients undergoing radical cystectomy, both with an open and robotic&#xD;
      approach. This study will thus help to clarify the actual impact of robotic surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2038</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2031</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>7 Years</target_duration>
  <primary_outcome>
    <measure>Number of participants who will die from bladder cancer</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Bladder Cancer Specific Mortality after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who will experience bladder cancer recurrence</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Bladder Cancer Recurrence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who will die from all causes</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>All cause mortality after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will die from bladder cancer after Robotic Surgery</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Robotic surgery specific impact on survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will experience bladder cancer recurrence after Robotic Surgery</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Robotic surgery specific impact on recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will experience surgical complications after Robotic Surgery</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Robotic surgery specific impact on surgical complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Quality of Life questionnaire after Robotic Surgery</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Robotic surgery specific impact on quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Quality of Life questionnaire according to Urinary diversions</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Urinary diversion specific impact on quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will experience surgical complications according to Urinary diversions</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Urinary diversion specific impact on surgical complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will experience bladder cancer recurrence according to Urinary diversions</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Urinary diversion specific impact on bladder cancer recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will die from bladder cancer according to Urinary diversions</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Urinary diversion specific impact on bladder cancer rmortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who will die from all causes according to Urinary diversions</measure>
    <time_frame>From enrollment to late follow-up, up to 7 years</time_frame>
    <description>Urinary diversion specific impact on all cause mortality after surgery</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Muscle-Invasive Bladder Carcinoma</condition>
  <condition>Oncology</condition>
  <condition>Recurrence</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Radical Cystectomy</arm_group_label>
    <description>Patients who underwent radical cystectomy for bladder cancer in our centre</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Cystectomy</intervention_name>
    <description>All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc...</description>
    <arm_group_label>Radical Cystectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is made up of patients who underwent radical cystectomy at AOU&#xD;
        Careggi, SOD Robotic Urological Surgery, Minimally Invasive and Renal Transplantation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age major or equal 18 years&#xD;
&#xD;
          -  Patients who will undergo radical cystectomy&#xD;
&#xD;
          -  Consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of willingness to participate&#xD;
&#xD;
          -  Further refusal to participate to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arcangelo Sebastianelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Careggi Hospital, University of Florence</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Serni, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simone Morselli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Morselli, MD</last_name>
    <phone>3473050852</phone>
    <email>simone.morselli.89@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Benemei, PhD</last_name>
    <email>silvia.benemei@unifi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Careggi University Hospital</name>
      <address>
        <city>Florence</city>
        <state>Tuscany</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Morselli, MD</last_name>
      <phone>3473050852</phone>
      <email>simone.morselli@unifi.it</email>
    </contact>
    <contact_backup>
      <last_name>Arcangelo Sebastianelli, MD</last_name>
      <email>arcangelo.sebastianelli@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sergio Serni, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauro Gacci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Morselli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rosaria Raspollini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arcangelo Sebastianelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riccardo Campi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donata Villari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Graziano Vignolini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saverio Giancane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pietro Spatafora, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Liaci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Gemma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Simone Morselli</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <keyword>Cystectomy</keyword>
  <keyword>Radical Cystectomy</keyword>
  <keyword>Ileal Conduit</keyword>
  <keyword>Neobladder</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Muscle Invasive Bladder Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

